Global Mpox Trends

Key figures

This report provides a comprehensive summary of data from the global mpox surveillance started by WHO in 2022, and strengthened during the ongoing public health emergency of international concern (PHEIC). For information on specific topics:

Topic	Relevant sections
Global distribution of clade Ib MPXV	Section 2.2
Clade II, Ia, and Ib MPXV in Africa	Section 3
Clade Ia and Ib MPXV in the Democratic Republic of the Congo	Section 4
Global epidemiology (largely clade IIb MPXV)	Section 5

For further information on the epidemiological situation in Africa, see Section 3

For further information on the epidemiological situation in Africa, see Section 3.

Values shown here are subject to case definitions used by their respective countries. For more information see Section 3.5.

For further information on the epidemiological situation in Africa, see Section 3

For further information on the distribution of MPXV clades see Section 2

Weekly trends in Africa

Data as updated weekly; from 01 January 2024 to 20 July 2025. Note that data shown here includes laboratory confirmed cases only. The most recent weeks presented in the epidemic curves should be interpreted with caution, as there are delays associated with reporting.

In the Democratic Republic of the Congo, a small number of cases are not represented on epidemic curves due to missing dates.

Totals for key countries

Summary of confirmed mpox cases in key countries
As of 20 Jul 2025
Country	Total cases in 2024	Total deaths in 2024	Total cases in 2025	Total deaths in 2025	Cases in the past six weeks1	Deaths in the past six weeks1	Clades detected in country	Date of last reported case
Democratic Republic of the Congo2	13 003	27	13 927	42	1096	3	Clades Ia and Ib	20 Jul 2025
Sierra Leone	0	0	4876	42	1061	22	Clade II (a and/or b)	20 Jul 2025
Uganda	1352	13	6230	35	843	4	Clade Ib	20 Jul 2025
Burundi	2946	1	1243	0	209	0	Clade Ib	20 Jul 2025
Kenya	31	1	225	4	105	3	Clade Ib	20 Jul 2025
Rwanda	82	0	40	0	0	0	Clade Ib	6 Jul 2025
1 From 09 Jun 2025 to 20 Jul 2025
2 Confirmed mpox cases in the Democratic Republic of the Congo are based on the laboratory database shared by the Ministry of Health with WHO. Confirmed deaths for 2024 are based on summary reports from the Ministry of Health. Annual breakdowns exclude 494 confirmed cases with dates prior to 2024 or with missing date information. For 2025, confirmed deaths are sourced from the clinical management database, also shared by the Ministry of Health with WHO, which includes data on confirmed mpox patients treated at designated mpox treatment centres.

Totals for Africa

Data as updated weekly; from 01 January 2022 to 20 July 2025. Note that data shown here refers to laboratory confirmed cases only, and are collected from the continent of Africa, across the WHO African and Eastern Mediterranean regions.

Total lab confirmed cases in week 29 2025

475

Total lab confirmed deaths in week 29 2025

8

Countries reporting cases in week 29 2025

16

Total lab confirmed cases in 2025

28 152

Total lab confirmed deaths in 2025

133

Countries reporting cases in 2025

24

Total lab confirmed cases since 2022

48 061

Total lab confirmed deaths since 2022

207

Countries reporting cases since 2022

31

Global totals

Data as updated monthly; from 01 January 2022 to 30 June 2025

Total lab confirmed cases in June 2025

4798

Total lab confirmed deaths in June 2025

21

Countries reporting cases in June 2025

50

Total lab confirmed cases in 2025

30 022

Total lab confirmed deaths in 2025

119

Countries reporting cases in 2025

79

Total lab confirmed cases since 2022

153 961

Total lab confirmed deaths since 2022

380

Countries reporting cases since 2022

137

Clades detected globally

Known clade distribution of MPXV as of 20 July 2025. Clade detection includes cases associated with local transmission and imported cases. Data is based on a combination of sequencing databanks, published literature, epidemiological links, and communication to WHO since 2022.

---

1 Overview

This report provides an overview of the mpox¹ epidemiological situation, based on global surveillance data reported to WHO from 01 January 2022, initiated due to the unprecedented human-to-human spread of monkeypox virus (MPXV) globally occurring in the same year.

¹ On of 28 November 2022, WHO recommended using the name mpox as a new name for monkeypox. The words were used synonymously for one year as the term monkeypox was phased out. The virus causing mpox is named monkeypox virus (MPXV).

² A summary of the geographic distribution of MPXV clades is included in Section 2.

Distinct MPXV clades and subclades are impacting diverse populations in different geographical regions, each exhibiting varied transmission dynamics². On 14 August 2024, under the provisions of the International Health Regulations (2005), the WHO Director-General determined that the upsurge of mpox in the Democratic Republic of the Congo (DRC) and in a growing number of countries in Africa constitutes a public health emergency of international concern (PHEIC). Its spread presents a public health risk to other Member States and requires a coordinated international response.

WHO conducted the latest global mpox rapid risk assessment in June 2025. Based on the available information, the risk is assessed as follows:

MPXV clade	Areas/populations affected	Overall risk level3
Clade Ib	Predominantly affecting non-endemic areas for mpox in the Democratic Republic of the Congo and neighbouring countries	High
Clade Ia	Primarily affecting endemic areas for mpox within the Democratic Republic of the Congo	Moderate4
Clade II	Observed in Nigeria and endemic countries in West and Central Africa	Moderate
Clade IIb	Associated with the global mpox epidemic first documented in 2022	Moderate

³ Possible risk levels are Low, Medium, High, and Very High

⁴ The situation in Kinshasa warrants specific focus and is linked to a higher risk of spread.

Please note that regardless of geographic area, epidemiological context, biological sex, gender identity or sexual behaviour, individual-level risk is largely dependent on individual factors such as exposure risk and immune status.

This report mainly focuses on confirmed cases and deaths as defined by WHO’s working case definition published in the surveillance, case investigation and contact tracing for mpox interim guidance. For countries with suboptimal testing rate, such as the Democratic Republic of the Congo, laboratory confirmed and suspected cases are both shown where possible to better describe the national epidemiological situation. Note that countries⁵ may use slightly different case definitions from those proposed by WHO, nevertheless all confirmed mpox cases need to have a positive laboratory test result.

⁵ Throughout this document, any use of the word country should be considered shorthand for a country, area, or territory

---

2 Summary of MPXV clades

Phylogenetic tree of all MPXV clades

Based on phylogenetic analysis, MPXV⁶ is divided into two major clades: clade I (one, formerly Congo Basin clade) and clade II (two, formerly West Africa clade). Each of these clades is further subdivided into two subclades: clade Ia and clade Ib within clade I; clade IIa and clade IIb within clade II.

⁶ MPXV genetic sequences are routinely shared within NCBI GenBank and GISAID databases.

• Clade Ia MPXV circulates within multiple countries in Central Africa and is associated with regular spillover from animal reservoirs with some onward human-to-human transmission. Mixing of virus sequences from these countries within the clade Ia phylogenetic tree shows cross-border movement of clade Ia viruses.

• Clade Ib MPXV started a major outbreak in 2023 in the eastern part of the Democratic Republic of the Congo⁷ and is undergoing sustained human-to-human transmission in several countries.

• Clade IIa MPXV has historically been detected primarily in animal species, with only limited human cases. However, more recently an increasing number of cases has been reported in several West African countries.

• Clade IIb MPXV, first detected in Nigeria, has undergone extended sustained circulation within humans since at least 2016 and has caused a large ongoing outbreak from 2022 to present. During the global outbreak, it has largely been associated with transmission among men who have sex with men. This outbreak reached its highest peak in August 2022, and continues to circulate at low levels in several countries.

⁷ More information on the geographical distribution of clades Ia and Ib MPXV can be seen in Section 4

2.1 Imported cases and clusters of clade I MPXV

The following table summarizes the available information on reported imported cases, and where applicable, onward cases of clade I MPXV. This table includes some imported cases from countries which have gone on to report community transmission⁸.

⁸ This table is available for download in Section 7

2.2 Geographical spread of clade Ib MPXV

This section gives an overview of clade Ib MPXV distribution in affected countries, as well as imported travel related cases, in line with the recommendations of the International Health Regulations (IHR, 2005) Emergency Committee on the upsurge of mpox in 2024.

---

Based on the presence of clade Ib mpox cases reported in the past six weeks, a country is classified as having:

Community transmission, if:

At least one reported case has no epidemiological link to travel or contact with a traveler from a country with known mpox transmission. This classification applies regardless of the total number of cases reported.

Cases linked to travel, if all reported cases are either:

Individuals who traveled to a country with known mpox transmission, were likely exposed there, and were diagnosed upon return or arrival.

OR

Individuals who did not travel themselves but had direct contact with someone who traveled to an affected country where the exposure occurred.

Unknown:

Insufficient information is available to determine if cases are due to community transmission or linked to travel.

---

---

Based on the presence of clade Ib mpox cases reported in the past six weeks, a country is classified as having:

Community transmission, if:

At least one reported case has no epidemiological link to travel or contact with a traveler from a country with known mpox transmission. This classification applies regardless of the total number of cases reported.

Cases linked to travel, if all reported cases are either:

Individuals who traveled to a country with known mpox transmission, were likely exposed there, and were diagnosed upon return or arrival.

OR

Individuals who did not travel themselves but had direct contact with someone who traveled to an affected country where the exposure occurred.

Previously reporting cases, if:

No new clade Ib MPXV cases have been reported for a period of more than six consecutive weeks since the last case, regardless of the previous transmission classification. Transmission is in control phase.

Unknown:

Insufficient information is available to determine if cases are due to community transmission or linked to travel.

---

Transmission classification of countries with active clade Ib MPXV spread

The following table includes countries reporting clade Ib MPXV in the past six weeks, and aims to classify their transmission dynamics into two ordinal categories⁹. If countries have not reported cases in the past six weeks, they are not considered to have active clade Ib transmission.

⁹ Transmission status is based on information reported to WHO, and does not account for instances where transmission may not be detected.

Clade Ib MPXV transmission classifications
Country1	Cases since Jan 2024	Cases in past 6 weeks	Transmission status2	Additional notes
Democratic Republic of the Congo	3 27 424	3 1096	Community transmission	-
Uganda	7582	843	Community transmission	-
Burundi	4189	209	Community transmission	-
Kenya	256	105	Community transmission	-
Zambia	172	84	Community transmission	-
United Republic of Tanzania	100	40	Community transmission	-
Congo	86	12	Community transmission	-
Malawi	59	32	Community transmission	-
Ethiopia	27	9	Community transmission	-
South Sudan	17	1	Community transmission	-
Mozambique	13	13	Community transmission	-
China	28	18	Cases linked to travel	-
The United Kingdom	15	3	Cases linked to travel	-
United States of America	5	1	Cases linked to travel	-
Australia	3	2	Cases linked to travel	-
Note: Imported cases are updated as of 28 July 2025 whereas case counts for countries classified as community transmission are updated as of 20 July 2025.
1 For countries classified as having cases linked to travel, only cases of mpox due to clade Ib MPXV are included. Cases in these countries for which clade and subclade classification is not determined or pending are not included. Note that multiple exported cases have been detected in travellers returning from United Arab Emirates, indicating likely community transmission in-country.
2 Countries with cases linked to travel also include instances where one to two generations of onward transmission have been reported, and linked to index cases.
3 Cases reported in Congo and the Democratic Republic of the Congo are known to be a mix of clade Ia and clade Ib MPXV.

Total cases of clade Ib MPXV by country

Clade Ib MPXV cases by country
Country	WHO region	Cases since Jan 2024	Cases in past 6 weeks
Democratic Republic of the Congo	African Region	1 27 424	1 1096
Uganda	African Region	7582	843
Burundi	African Region	4189	209
Kenya	African Region	256	105
Zambia	African Region	172	84
Rwanda	African Region	122	0
United Republic of Tanzania	African Region	100	40
Congo	African Region	86	12
Malawi	African Region	59	32
China	Western Pacific Region	28	18
Ethiopia	African Region	27	9
South Sudan	African Region	17	1
The United Kingdom	European Region	15	3
Mozambique	African Region	13	13
Germany	European Region	10	0
India	South-East Asia Region	10	0
South Africa	African Region	8	0
Belgium	European Region	6	0
Qatar	Eastern Mediterranean Region	5	0
Thailand	South-East Asia Region	5	0
United States of America	Region of the Americas	5	1
France	European Region	3	0
Australia	Western Pacific Region	3	2
Angola	African Region	2	0
United Arab Emirates	Eastern Mediterranean Region	2	0
Canada	Region of the Americas	1	0
Oman	Eastern Mediterranean Region	1	0
Pakistan	Eastern Mediterranean Region	1	0
Sweden	European Region	1	0
Zimbabwe	African Region	1	0
Brazil	Region of the Americas	1	0
Switzerland	European Region	1	0
Italy	European Region	1	0
Note: Imported cases are updated as of 28 July 2025 whereas case counts for countries classified as community transmission are updated as of 20 July 2025.
1 Cases reported in Congo and the Democratic Republic of the Congo are known to be a mix of clade Ia and clade Ib MPXV.

Global map of clade Ib MPXV spread

The following map shows countries reporting clade Ib MPXV in the past six weeks, and aims to classify their transmission dynamics into two ordinal categories. If countries have not reported cases in the past six weeks, they are not considered to have active clade Ib transmission.

Timeline of clade Ib MPXV spread

Clade Ib MPXV has been reported in the following countries. The timeline below shows the date of report to WHO, place of travel, and number of onward cases reported.

Cases which led to onward cases are shown in red, while cases with no onward transmission are shown in blue.

Epidemic curve of imported clade Ib cases over time

Note this figure does not include onward cases derived from imported cases.

2.3 Geographical spread of clade Ia MPXV

This section gives an overview of clade Ia MPXV distribution in affected countries, as well as imported travel related cases. MPXV clade Ia is endemic in several countries in Central Africa, and is associated with regular spillover from animal reservoirs. However, like clade Ib, some sublineages of clade Ia have recently been linked to sustained human to human transmission.

---

Endemic:

Countries with a historical reporting of clade Ia MPXV cases, likely due to zoonotic spillover events from local animal fauna

Community transmission:

Non-endemic countries reporting ongoing local transmission, including unlinked cases affecting population groups throughout the community

Cases linked to travel:

Countries reporting cases likely infected in other countries, including instances where one to two generations of onward transmission have been reported in country, and linked to index cases.

Unknown:

Insufficient information is available to determine if cases are due to community transmission or linked to travel.

---

Status of countries reporting clade Ia MPXV

The following table includes countries reporting clade Ia MPXV, and aims to classify their transmission dynamics into three ordinal categories.

Transmission status by country: clade Ia MPXV
1 January 2022 to 20 July 2025
Country	WHO Region	Transmission status1
Cameroon	African Region	Endemic
Central African Republic	African Region	Endemic
Congo	African Region	Endemic
Democratic Republic of the Congo	African Region	Endemic
Sudan	Eastern Mediterranean Region	Endemic
China	Western Pacific Region	Cases linked to travel
Ireland	European Region	Cases linked to travel
Türkiye	European Region	Cases linked to travel
Note: Imported cases are updated as of 28 July 2025 whereas case counts for countries classified as community transmission are updated as of 20 July 2025.
1 Countries with cases linked to travel also include instances where one to two generations of onward transmission have been reported, and linked to index cases.

Global map of clade Ia MPXV spread

---

3 Situation in Africa

This section is jointly authored by the WHO Regional Office for Africa, the WHO Regional Office for the Eastern Mediterranean¹⁰ and WHO Headquarters.

¹⁰ On the African continent there are 47 Member States in the WHO African Region and seven in the WHO Eastern Mediterranean Region.

Since 1 January 2022, cases of mpox have been reported to WHO from 31 Member States across Africa. As of 20 July 2025 , a total of 48 061 laboratory confirmed cases, including 207 deaths, have been reported to WHO.

In the past twelve months, as of 20 July 2025, 28 countries have reported 40 509 confirmed cases, including 169 deaths. The three countries with the majority of the cases in the last 12 months are Democratic Republic of the Congo, (n = 21 464), Uganda, (n = 7579), and Sierra Leone, (n = 4876).

In the Democratic Republic of the Congo a significant number of suspected mpox cases, that are clinically compatible with mpox remain untested due to limited diagnostic capacity and thus never get confirmed¹¹. Moreover, not all countries have robust surveillance systems¹² for mpox, meaning reported case counts are likely underestimating the extent of community transmission.

¹¹ This indicator should be interpreted with caution, as suspected mpox cases are recorded according to varying national case definitions.

¹² Surveillance may also be affected by differences in case definitions across countries. These can be viewed in Section 3.5.

3.1 Outbreak status and MPXV clade distribution

The distribution of clades reported in Africa, and the outbreak status of countries on the continent is shown in the maps below. The distribution of reported mpox clades in Africa is also shown below.

Maps can be clicked to view on a larger scale.

Outbreak status

Outbreak status of countries is shown below¹³.

¹³ Countries with active mpox transmission are classified as those that have reported cases to WHO within the past 42 days. If a country does not share information on mpox cases or provide regular zero-case reporting to WHO or any other open-access resources, its outbreak status may not accurately reflect its current situation on the map.

MPXV clade distribution

Clade distribution is shown below¹⁴. Note that subnational distributions of MPXV clades are not captured in this figure.

¹⁴ In many cases, sequencing may not capture all circulating clades, leading to under-representation of where clades are circulating.

Confirmed cases in the past six weeks

3.2 Epidemic curves

Epidemic curve shown by week for cases reported up to 20 Jul 2025. The most recent weeks presented in the epidemic curves should be interpreted with caution, as there are delays associated with reporting.

3.2.1 Confirmed cases

The following epidemic curve shows the number of confirmed cases by week for countries in Africa. Use the dropdowns to select the time range and countries to display.

In the Democratic Republic of the Congo, a small number of cases are not represented on epidemic curves due to missing dates.

Time range

Year to date Past 12 months 2022 to present

Countries

Clades reported

Any clades Clade Ia MPXV only Clade Ib MPXV only Clade II MPXV only Clades Ia and Ib MPXV Clades Ia and II MPXV

3.2.2 All cases in the Democratic Republic of the Congo

All cases, including suspected and lab confirmed cases are shown from 2024. We exceptionally highlight the Democratic Republic of the Congo due to the testing shortage in country, where only a third of cases in 2024 were tested.

---

3.3 Maps

Maps can be clicked to view on a larger scale. Note that data are only shown for Africa - data from elsewhere are reflected in the global sections of the report.

Confirmed cases past 12 months

Confirmed cases past six weeks

Confirmed deaths in past 12 months

Confirmed deaths in past six weeks

3.4 Data by country

Data by country is available in table format here.

3.4.1 Laboratory confirmed cases

Summary of Laboratory confirmed mpox cases

As of 20 Jul 2025

¹ From 09 Jun 2025 to 20 Jul 2025

² Confirmed mpox cases in the Democratic Republic of the Congo are based on the laboratory database shared by the Ministry of Health with WHO. Annual breakdowns exclude 494 confirmed cases with dates prior to 2024 or with missing date information. Confirmed deaths for 2024 are based on summary reports from the Ministry of Health. For 2025, confirmed deaths are sourced from the clinical management database, also shared by the Ministry of Health with WHO, which includes data on confirmed mpox patients treated at designated mpox treatment centres.

3.5 Case definitions

This section includes the national case definition used in African countries in order to provide more context for the interpretation of data, especially of suspected cases.

Case definitions for suspected cases are shown for the following countries below:

Democratic Republic of the Congo

Suspected case:

A person with sudden onset of high fever followed by a vesiculopustular rash predominantly on the face and present on the palms of the hands and soles of the feet; OR presence of at least 5 smallpox-like scars,

OR

Any person with fever > 38.3 °C (101 F), severe headache, lymphadenopathy, back pain, myalgia, and severe weakness, followed 1-3 days later by a progressive rash that often begins on the face (more dense) and then spreads elsewhere on the body, including the soles of the feet and palms of the hands.

Confirmed case:

Any case for which the clinical and epidemiological diagnosis of mpox has been laboratory confirmed.

---

4 Situation in the DRC

Here, we exceptionally present an overview of the ongoing situation in the Democratic Republic of the Congo, in agreement with the national Ministry of Public Health.

The current spread of mpox in the Democratic Republic of the Congo is attributed to two increasingly interspersed outbreaks:

• The spread of clade Ia MPXV, largely in endemic provinces of the country¹⁵, and

• The spread of clade Ib MPXV, which emerged in 2023 in the South Kivu province¹⁶.

¹⁵ Endemic provinces are: Equateur, Sankuru, Tshuapa, Tshopo, Nord Ubangi, Bas Uele, Sud-Ubangi, Mongala, Kwilu, Maindombe, and Maniema, where in the DRC, an endemic area is considered to be one which has reported mpox cases for at least five consecutive years.

¹⁶ Cases of clade Ib MPXV have been detected in Haut Katanga, Ituri, Kasai, Kinshasa, Kongo Central, Lomami, Lualaba, Maindombe, Mongala, Nord Kivu, Sud-Kivu, Tanganyika, and Tshopo.

Clade Ia MPXV is associated with zoonotic spillover from animal reservoirs followed by some human-to-human transmission. Emerging evidence shows that human-to-human transmission has been sustained in Kinshasa since the second half of 2024. In contrast, epidemiological and sequencing information show that clade Ib MPXV is associated predominantly with human-to-human transmission.

In this section, clade distribution across provinces is based on sequencing data provided by the Democratic Republic of the Congo National Institute of Biomedical Research (INRB). Geographical representation may be incomplete, and the actual clade distribution could be broader and more nuanced than currently presented.

The report presents trends based on three key data sources:

Source	Description	Usage
Syndromic mpox surveillance system	Data on suspected mpox cases and deaths collected via the Integrated Disease Surveillance database (IDS). Cases that are tested and are negative are not retrospectively removed once reported. Data delay of 1-2 weeks.	Overall case and death numbers, and trends in cases.
Laboratory data	Mpox suspected cases that are sampled and tested. Data delay varies between different provinces and the distance from the reference laboratory.	Confirmed case numbers and trends in confirmed cases.
Case-based epidemiological data	Detailed information about all investigated cases, including case classification based on sampling and testing. Completeness and delays vary between different provinces.	Demographic characteristics of cases
Sequencing metadata	Basic case-based information about confirmed cases that are sequenced.	Information on the clade distribution of MPXV in the country

All surveillance data are subject to reporting delays, and data cleaning is ongoing. As a result, sub-national case counts in this section may lag behind those reported at the national level. Mpox surveillance coverage and completeness in the Democratic Republic of the Congo varies over geographic space and time, and in some cases data sources may not be fully harmonised.

4.1 Situation summary

Distribution of MPXV sequences

The map is generated using sequences that are publicly available in the INRB, GISAID and Genbank databases. MPXV sequences from Democratic Republic of the Congo are shown from October 2023, with the latest sequence here sampled on 01 July 2025.

Trends in all cases by province

Trends shown for the 16 provinces reporting the highest numbers in the past six weeks. Data shown for all cases, via syndromic surveillance system.

Recent cases by health zone

Data shown for all cases, via syndromic surveillance system.

---

4.2 Genomic surveillance

In this subsection, we present visualizations of sequences that are publicly available in the INRB, GISAID and Genbank databases. The latest MPXV sequence from the Democratic Republic of the Congo was sampled on 01 July 2025.

Important

When interpreting these data, it is important to note that the availability of sequences is not uniform across time and space, and that the distribution of sequences may not be representative of the true distribution of clades in the country.

Samples associated with clade Ib MPXV were first collected in late 2023 - the designation of this lineage in 2024 retrospectively classified all previously identified sequences as clade Ia MPXV (previously they would be considered clade I). Therefore, all sequences identified before 2023 are retrospectively attributable to ancestral clade Ia MPXV.

Sequencing from 2023

The map below shows the distribution of MPXV sequences from the Democratic Republic of the Congo from 2023. The color of each province represents the proportion of sequences that are clade Ib MPXV¹⁷.

¹⁷ Sequences are obtained from metadata shared by the Democratic Republic of the Congo National Institute of Biomedical Research (INRB), and from publicly available sequences on Genbank and GISAID.

Classification of provinces

4.3 Laboratory testing

This section presents indicators related to mpox testing in the Democratic Republic of the Congo, including the proportion of suspected cases sampled and test positivity among sampled cases over time. Tests are performed by a laboratory network throughout the country using conventional PCR testing and GeneXpert PCR.

Throughout this section, sampling percentages are calculated as the number of cases sampled (based on national laboratory line list data) divided by the number of cases reported through the syndromic surveillance system for the geographic unit. Please note, since this calculation draws from two separate data sources, date misalignments may lead to discrepancies.

Test positivity is calculated as the number of positive PCR samples out of the total tested for each geographic unit.

Laboratory testing by geographic area
from 01 Jan 2024 to 13 Jul 2025
	% suspected cases tested	% tested cases positive
Kinshasa	-	39.8%
Sud-Kivu	40.3%	66.2%
Nord Kivu	-	34.5%
Endemic provinces	21.7%	55.2%

4.3.1 National level

Monthly percentages of suspected cases for whom a sample was collected and monthly percentage of confirmed cases through laboratory testing. Sampling and confirmation percentages follow the same calculation methods described above. Positivity rates are based solely on national laboratory line list data. Wider confidence intervals indicate smaller sample sizes or more variable positivity^{18 19}.

¹⁸ Confidence intervals are calculated via the binomial distribution.

¹⁹ The decrease in the proportion of cases sampled after the PHEIC declaration in August 2024 is linked to the increase in case detection. Similarly, the decrease in the proportion of cases positive is influenced by the increase in testing after August 2024.

4.3.2 By province

Sampling percentages are not shown for Kinshasa, as all cases are sampled. Nord Kivu is excluded due to differences in syndromic case reporting over time.

Variations in positivity rates may reflect differences in disease incidence as well as sampling and testing capacity and strategy over time^{20 21}.

²⁰ Confidence intervals are calculated via the binomial distribution.

²¹ The decrease in the proportion of cases sampled after the PHEIC declaration in August 2024 is linked to the increase in case detection. Similarly, the decrease in the proportion of cases positive is influenced by the increase in testing after August 2024.

4.3.3 By province and age group

Monthly percentages of suspected cases for whom a sample was collected and confirmed through laboratory testing by age across four geographic areas in the Democratic Republic of the Congo. Sampling percentages are not shown for Kinshasa, as all cases are sampled. Nord Kivu is excluded due to differences in syndromic case reporting over time.

% suspected cases sampled and %tested cases positive by age and geographic area
from 01 Jan 2024 to 13 Jul 2025
	% Suspected Cases Tested			% Tested Cases Positive
	0-4 yrs	5–14 yrs	15+ yrs	0–4 yrs	5–14 yrs	15+ yrs
Kinshasa	-	-	-	46.4%	49.5%	66.6%
Sud-Kivu	20.7%	42.0%	43.5%	54.5%	51.8%	65.6%
Nord Kivu	-	-	-	25.3%	25.5%	35.4%
Endemic provinces	10.9%	25.3%	28.0%	48.3%	49.8%	52.3%

4.4 Data tables

Note

Total cases and death columns reflect data for 2024 and 2025.

Laboratory confirmed cases

Note

This table is generated from multple data sources. In some cases where delays in reporting do not match, the percentage of cases tested may be higher than the number of total cases.

Summary of mpox testing by province, Democratic Republic of Congo

as of 13 Jul 2025

¹ Data shown for all cases, via syndromic surveillance system.

² from 02 Jun 2025 to 13 Jul 2025

³ In Nord-Kivu, the number of tested cases is higher than the total cases in 2024, due to the fact that during this time discarded cases are not included in the total cases

All cases by Health Zone

The following table is shown for the health zones with the highest numbers of recorded cases in the past six weeks.

Summary of most affected health zones in past 6 weeks, Democratic Republic of Congo

as of 13 Jul 2025

¹ Data shown for all cases, via syndromic surveillance system.

² from 02 Jun 2025 to 13 Jul 2025

4.5 Maps

Distribution of cases and deaths can be explored in the Democratic Republic of the Congo at the provincial and health zone levels²². The maps are interactive and can be explored by clicking on the layers in the legend to show or hide the different layers. Note that the legend scale varies across layers.

²² Note the administrative levels of DRC are province (admin 1), health zone (admin 2) and health area (admin 3).

Note

Total cases and deaths reflect data for 2024 and 2025.

4.5.1 Provincial level

4.5.2 Health zone level

Disclaimer

The designations employed and the presentation of the material in this publication do not imply the expression of any opinion whatsoever on the part of WHO concerning the legal status of any country, territory, city or area or of its authorities, or concerning the delimitation of its frontiers or boundaries. Dotted and dashed lines on maps represent approximate border lines for which there may not yet be full agreement.

4.6 Epidemic curves

All cases by province

Trends shown for the 16 provinces reporting the highest numbers of cases in the past six weeks. Data shown for all cases, via syndromic surveillance system.

Confirmed cases by province

Trends in confirmed cases shown for the 16 provinces reporting the highest numbers of confirmed cases in the past six weeks. Note that confirmed cases are highly sensitive to the availability of testing which is variable over space and time.

Total cases

Trends as per the syndromic surveillance data (IDSR) shown for individual provinces.

Indicator

Cases Deaths

Province

Bas Uele Equateur Haut Katanga Haut Lomami Haut Uele Ituri Kasai Kasai Central Kasai Oriental Kinshasa Kongo Central Kwango Kwilu Lomami Lualaba Maindombe Maniema Mongala Nord Kivu Nord Ubangi Sankuru Sud-Kivu Sud-Ubangi Tanganyika Tshopo Tshuapa

Health Zone

All Aketi Ango Bili Bondo Buta Dingila Likati Monga Poko Titule Viadana

Confirmed cases

Trends shown for individual provinces via the laboratory database.

Province

Bas Uele Equateur Haut Katanga Haut Lomami Haut Uele Ituri Kasai Kasai Central Kasai Oriental Kinshasa Kongo Central Kwango Kwilu Lomami Lualaba Maindombe Maniema Mongala Nord Kivu Nord Ubangi Sankuru Sud-Kivu Sud-Ubangi Tanganyika Tshopo Tshuapa

---

4.7 Severity

Most mpox deaths in the country are not confirmed by laboratory testing and they are reported through the syndromic surveillance system. Mpox endemic provinces report the highest number of deaths and have a higher case fatality ratio (CFR) compared to recently affected provinces.

Endemic provinces are considered: Equateur, Sankuru, Tshuapa, Tshopo, Nord Ubangi, Bas Uele, Sud-Ubangi, Mongala, Kwilu, Maindombe, and Maniema

²³ Confidence intervals are calculated via the binomial distribution.

Information from available sequences shows that cases in these provinces are associated with a dominance of clade Ia MPXV, although CFR may be affected by demographic factors, healthcare access, reporting practices, and comorbidities. CFR is calculated as the number of deaths divided by the number of cases, with 95% confidence intervals shown²³.

CFR estimates are derived from all cases - for this reason they may be influenced by regional differences in surveillance.

Region	Deaths	CFR	95% CI
Endemic provinces	1698	2.5%	2.4% - 2.7%
Sud Kivu	51	0.2%	0.1% - 0.2%
Kinshasa	16	0.3%	0.2% - 0.5%
Nord Kivu	3	0.0%	0.0% - 0.1%

Age group	CFR	95% CI
Endemic provinces
0-4	3.3%	3.1% - 3.6%
5-14	2.2%	2.0% - 2.4%
15+	2.0%	1.8% - 2.2%
Kinshasa
0-4	1.4%	0.6% - 3.0%
5-14	0.2%	0.0% - 0.9%
15+	0.2%	0.1% - 0.3%
Sud Kivu
0-4	0.2%	0.2% - 0.4%
5-14	0.0%	0.0% - 0.1%
15+	0.2%	0.1% - 0.3%

All cases

By age group

Note only provinces with more than 10 deaths are included below.

---

4.8 Case demographics

This section presents the age and sex distribution of mpox cases, suspected and confirmed, in different geographic location, and aims to highlight the differences in demographics between cases reported in endemic and recently affected provinces. Data are presented from 2024, with data from recent weeks shown separately to identify any changes in transmission dynamics.

The pyramid outlined in black represents the population distribution in the different settings.

4.8.1 Age-sex pyramids by location

Suspected cases are not shown in Kinshasa, as nearly all cases are tested.

Endemic provinces are: Equateur, Sankuru, Tshuapa, Tshopo, Nord Ubangi, Bas Uele, Sud-Ubangi, Mongala, Kwilu, Maindombe, and Maniema.

Nord Kivu

The age-sex pyramids for Nord Kivu show a higher concentration of confirmed cases among adults, while suspected cases are primarily reported among children. These variations have changed substantially over time, and are likely attributable to distinct regional transmission dynamics, confounding diseases in suspected cases, and differences in healthcare access or reporting practices across space and time.

Sud Kivu

The age-sex pyramids for Sud Kivu show a higher concentration of confirmed cases among adults, while suspected cases are primarily reported among children. These variations have changed substantially over time, and are likely attributable to distinct regional transmission dynamics, confounding diseases in suspected cases, and differences in healthcare access or reporting practices across space and time.

Kinshasa

Cases in Kinshasa are primarily reported among adults, with a predmoninance of male cases, especially among confirmed cases. This is likely linked to the transmission through sexual contact, involving sex workers and their clients in Kinshasa.

Endemic provinces

In endemic provinces, the age-sex distribution remain relatively consistent across confirmed and suspected cases. Cases are approximately equally distributed between males and females, and incidence is highest in children under 15 years of age.

4.8.2 Age and sex in recent weeks

The majority of cases are tested in Kinshasa, meaning there are very few suspected cases.

Endemic provinces are: Equateur, Sankuru, Tshuapa, Tshopo, Nord Ubangi, Bas Uele, Sud-Ubangi, Mongala, Kwilu, Maindombe, and Maniema.

Nord Kivu

Sud Kivu

Kinshasa

Endemic provinces

---

5 Global Situation

Year	Total Cases	Total Deaths	Countries reporting cases
2022	84 906	138	108
2023	9696	45	76
2024	26 350	78	85
2025	30 022	119	79

This section of the report includes only confirmed and probable mpox cases and deaths at a global level.

Note

Since 2022 to date, the vast majority of mpox cases are attributable to clade IIb MPXV²⁴. The data presented here are based on the most recent complete month of data reported to WHO as of 30 June 2025.

²⁴ Not all cases can be attributed to a specific MPXV clade. While some countries have sporadic imported cases of other clades, widespread community transmission of other clades has not been reported to WHO.

Data in this section are derived from a combination of two datasets:

1. Aggregate case reporting, collected monthly²⁵ and,
2. Detailed case-based data for a subset of cases reported directly from Member States to WHO²⁶.

²⁵ Global aggregated data are collected through direct reporting from Member States to WHO and its partners or from official country sources.

²⁶ Data from cases are reported according to the WHO minimum dataset under the International Health Regulations (IHR 2005) Article 6.

Where information is available, the majority of cases associated with clade IIb MPXV continue to be adult, male, and self-identified as men who have sex with men.

Globally, cases of mpox peaked in August 2022 - while significantly fewer cases are reported now, transmission of clade IIb MPXV continues globally.

5.1 Key figures

Year	Total Cases	Total Deaths	Countries reporting cases
2022	83 937	122	96
2023	9194	38	67
2024	10 730	27	65
2025	3876	6	58
Note the case and death counts correspond to cases reported outside Africa.

Global epidemic curve

Epidemic curve shown for past year by month for cases reported up to 30 Jun 2025 to avoid showing incomplete months of data.

Age and sex outside of Africa

Age and sex shown for confirmed cases reported outside of Africa, for the past twelve months.

Map of cases in past year

Map of cases in past month

5.2 Reporting summary

In 30 June 2025, a total of 31 countries outside Africa reported 426 new confirmed cases and 1 new deaths.

From January 2022 and as of 30 June 2025, detailed case data for countries outside Africa was reported for 103 089 cases, representing 67.0% of all cases reported during this period.

Cases reported by region

Total mpox cases, by WHO region
Data from January 2022 to June 2025
WHO region	Total cases1	Total deaths1	Cases in last 12 months2	Cases in May 2025	Cases in Jun 2025	Monthly % change in cases	Countries reporting cases in past month
Region of the Americas	69 404	151	4858	321	84	−74.0%	6
African Region	46 195	186	39 101	6239	4372	−30.0%	20
European Region	30 410	10	2881	291	221	−24.0%	18
Western Pacific Region	5998	16	2456	152	115	−24.0%	4
South-East Asia Region	1043	14	118	10	5	−50.0%	2
Eastern Mediterranean Region	911	3	52	2	1	−50.0%	1
1 From 1 January 2022
2 From July 2024

Cases reported by country

Total Mpox cases, by WHO region

¹ Counts are based on the global monthly reported data for which the latest month is shown.

² Cases shown include those in mainland China (2751), Hong Kong SAR (78), Taipei (468), and Macao (2)

Countries reporting first cases

Countries reporting first cases in the last month
Data as of June 2025
Country	WHO Region	Cases

Reporting coverage for detailed case data

The following table shows the proportion of confirmed cases reported in detailed case data for each WHO region²⁷.

²⁷ Case-based data reported by the Democratic Republic of the Congo is not included in this table. Cased based data from the Democratic Republic of the Congo is complete, and shown in Section 4

Mpox reporting completeness
From NA to 30 Jun 2025
	Total Confirmed Cases	Total Detailed Confirmed Cases1	% Detailed Cases reported
Region of the Americas	69 404	67 816	97.7%
African Region	46 195	672	1.5%
European Region	30 410	30 184	99.3%
Western Pacific Region	5998	3252	54.2%
South-East Asia Region	1043	1036	99.3%
Eastern Mediterranean Region	911	129	14.2%
1 Note that in rare cases total detailed cases may exceed total confirmed cases due to ongoing data cleaning issues

5.3 Trends in cases

5.3.1 Trends by WHO region

Time range

Past 12 months 2022 to present

Indicator

Confirmed cases Confirmed deaths

Location relative to Africa

WHO region

5.3.2 Trends by country

Time range

Past 12 months 2022 to present

Indicator

Confirmed cases Confirmed deaths

Country

Albania Andorra Angola Argentina Aruba Australia Austria Azerbaijan Bahamas Bahrain Barbados Belgium Benin Bermuda Bolivia (Plurinational State of) Bosnia and Herzegovina Brazil Bulgaria Burundi Cambodia Cameroon Canada Central African Republic Chile China Colombia Congo Costa Rica Côte d’Ivoire Croatia Cuba Curaçao Cyprus Czechia Democratic Republic of the Congo Denmark Dominican Republic Ecuador Egypt El Salvador Estonia Ethiopia Finland France Gabon Georgia Germany Ghana Gibraltar Greece Greenland Guadeloupe Guam Guatemala Guinea Guyana Honduras Hungary Iceland India Indonesia Iran (Islamic Republic of) Ireland Israel Italy Jamaica Japan Jordan Kenya Kosovo Lao People's Democratic Republic Latvia Lebanon Liberia Lithuania Luxembourg Malawi Malaysia Malta Martinique Mauritius Mexico Monaco Montenegro Morocco Mozambique Nepal Netherlands New Caledonia New Zealand Nigeria North Macedonia Norway Oman Pakistan Panama Paraguay Peru Philippines Poland Portugal Qatar Republic of Korea Republic of Moldova Romania Russian Federation Rwanda Saint Martin San Marino Saudi Arabia Serbia Sierra Leone Singapore Slovakia Slovenia South Africa South Sudan Spain Sri Lanka Sudan Sweden Switzerland Thailand The United Kingdom Togo Trinidad and Tobago Türkiye Uganda Ukraine United Arab Emirates United Republic of Tanzania United States of America Uruguay Venezuela (Bolivarian Republic of) Viet Nam Zambia Zimbabwe

5.4 Global Maps